Project description
New therapeutic targets for rare disorders and cancer
Phosphoinositide 3-kinase (PI3K) signalling is a key pathway that regulates cell growth, metabolism, and survival. Phosphatase and tensin homolog (PTEN) serves as a negative regulator of the pathway and has a tumour-suppressive role. The scope of the EU-funded PIPgen project is to exploit existing knowledge on the involvement of PI3K/PTEN in cancer to understand the implication of the pathway in monogenic rare diseases, such as overgrowth syndromes, primary immunodeficiencies and cognitive deficiencies. Conversely, information on PI3K in rare diseases will be fed back to cancer. The generated basic science results will lay the foundation for the design of novel therapies for the numerous rare diseases that affect millions of citizens across Europe.
Fields of science
Programme(s)
Coordinator
08916 Badalona
Spain
See on map
Participants (10)
WC1E 6BT London
See on map
75654 Paris
See on map
CB2 1TN Cambridge
See on map
75006 Paris
See on map
3015 GD Rotterdam
See on map
1081 HV Amsterdam
See on map
6525 GA Nijmegen
See on map
48160 Derio Vizcaya
See on map
10126 Torino
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08950 Esplugues Del Llobregat
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.